In addition, the NK92-CD64/16A cells efficiently captured the tumor-targeting mAbs Erbitux/cetuximab and Rituxan/rituximab, as well as the fusion protein L-selectin/Fc (Figure 3C). This evidence concerns the gene SELL and neoplasm.